Open Targets Platform summer 🌻 release is out with enhanced data and improved therapeutic hypothesis-building capabilities. We continue our sustained effort to connect the necessary dots and understand the risks/benefits of early drug discovery decision-making.

Deploy your own Open Targets Platform in your environment of choice! The latest new contribution to life sciences by the Open Targets Team, that will open the doors to improved reproducibility, collaborations, prototyping, outreach and training activities

Genetic evidence halves the odds of early clinical trial stoppage 🧬💊 Published today in Nature Genetics, Olesya Razuvayevskaya trained a machine learning classifier to analyse the free-text reasons explaining why 28,842 clinical trials stopped 3 key points: nature.com/articles/s4158…

Why do clinical trials stop? Researchers from Open Targets and EMBL-EBI have developed a machine learning model to analyse clinical trial data. They found a correlation to suggest that trials less supported by genetic evidence are more likely to fail. ebi.ac.uk/about/news/res…

Join the Club! 🤝 A new study characterises types of Open Science Partnerships, featuring Open Targets as an example of “The Club” This research suggests how OSPs can best be designed for their goals, and provides a framework to understand their impact nature.com/articles/s4159…

Job alert 🚨: join us for a post-doc in beautiful Cambridgeshire !

Thrilled to see our work on murine oesophageal #Epithelioids published in Nature Genetics, after many years of hard work alongside Albert_Herms during our postdoc at Phil Jones' lab @Sangerinstitute and built on the foundational work by Maria Alcolea nature.com/articles/s4158…

The Open Targets Platform Spring 🌼 release brings a step-change in how we address common disease genetics. We included the results of a large-scale analysis on GWAS and functional genomics studies to inform target selection further 🧬👩‍💻 blog.opentargets.org/a-step-change-…